SKYRIZI (Abbvie Pty Ltd)
Product name
SKYRIZI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
217 working days (255)
Active ingredients
risankizumab
Registration type
NCE/NBE
Indication
SKYRIZI (solution for injection) is indicated for the treatment of moderate to severe plaque psoriasis in adults (18 years or older) who are candidates for phototherapy or systemic therapy.